ProCE Banner Activity

HPTN 083: HIV Infections in the Yr 1 Unblinded Period in MSM and TGW Receiving Injectable CAB for HIV PrEP

Slideset Download
Conference Coverage

Efficacy advantage of long-acting CAB over FTC/TDF for HIV PrEP persisted 1 year after unblinding, with 3 new cases of INSTI mutations observed.

Released: October 27, 2022


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare